AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report sent to investors on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $32.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $28.00 target price for the company. Finally, Leerink Partners started coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Down 1.9%

AGMB opened at $15.90 on Tuesday. AgomAb Therapeutics has a one year low of $12.66 and a one year high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.